Clinical Trial Search

Primary: Progression-free Survival Rate at 3 Years — 92.2; 93.7; 58.8 percentage of participants

Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234

Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204

Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…

Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients

Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants

Primary: Overall Objective Response — 1; 0; 1; 0 participants

Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas

Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…

Primary: Response Rate (Complete and Partial Response) — 7 Participants

Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315

Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants

Primary: Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months — 93; 85; 51; 73 percentage of patients

Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 Participants

Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants

Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants

Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants

Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…

Primary: Response Rate

Primary: Sensitivity (SBR) — 5.49 ratio

Primary: Progression-free Survival

Primary: Extent of Resection — 24; 25 participants

Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants

Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants

Primary: Progression Free Survival — 70 percentage of no progression

Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05

Primary: Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects — 0; 0; 0 Participants

Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09

Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities

Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…